Sonoma Pharmaceuticals (SNOA) Asset Writedowns and Impairment (2011 - 2015)

Sonoma Pharmaceuticals' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at -$834000.0 for Q1 2015.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$834000.0 in Q1 2015; TTM through Mar 2015 was $3.8 million, a N/A change from a year earlier, with the FY2022 full-year figure at -$125000.0, up 86.16% from the prior year.
• Asset Writedowns and Impairment retreated to -$834000.0 in Q1 2015 per SNOA's latest filing, from $4.6 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $4.6 million in Q4 2014 and bottomed at -$834000.0 in Q1 2015.
• The 5-year median for Asset Writedowns and Impairment is $104000.0 (2011), against an average of $331666.7.
• Across the five-year window, Asset Writedowns and Impairment soared 158.62% in 2012 and sank 73.63% in 2013, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $128000.0 in 2011, then climbed by 23.44% to $158000.0 in 2012, then sank by 84.81% to $24000.0 in 2013, then surged by 19275.0% to $4.6 million in 2014, then sank by 117.94% to -$834000.0 in 2015.
• Per Business Quant, the three latest SNOA Asset Writedowns and Impairment figures stand at -$834000.0 (Q1 2015), $4.6 million (Q4 2014), and $24000.0 (Q3 2013).